The AKITA® JET Inhalation System is a reusable, breath-actuated jet nebuliser designed to aerosolize liquid medications.

It guides the patient to inhale with a pre-set inspiratory flow rate and inhalation volume/time to ensure precise and targeted drug delivery to the patient’s lungs. The device achieves a more favorable regional deposition (higher peripheral, and lower oropharyngeal and central deposition) and lower interpatient lung deposition variability, compared with conventional nebulisers [1-5].

AKITA®JET is a CE marked medical device (CE0123)

  • The AKITA® JET can be used with medication for the treatment of diseases of the respiratory passages and lungs.

  • The system is suitable for use at home, hospital and general practice for temporary oral inhalation of a liquid medication prescribed or recommended by a physician.

  • The AKITA® JET Inhalation System must be used only on conscious, cooperative patients from the age of 3 years onwards and is not intended for life support purposes.

IMPORTANT NOTE: AKITA® JET is not for sale on the US market

1Vogelmeier C, Kardos P et al. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. Eur Respir J 2015; 45: 1273 – 1282.
2Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of α1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22: 263–267.
3Fischer A, Stegemann J, Scheuch G, et al. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res 2009; 14: Suppl. 4, 71–77.
4Scheuch G, Brand P, Meyer T, et al. Regional drug targeting within the lungs by controlled inhalation with the AKITA-inhalation system. Respir Drug Del VIII 2002; 2: 471–474.
5Kohler, E., Sollich, V., Schuster-Wonka, R., et al. Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. Journal of Aerosol Medicine. 2005: 18 (4): 386-395.